ALBERTDAVD · Albert David Ltd · Biotechnology & Drugs
ALBERTDAVD · Albert David Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
17.0% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹101 Cr
Revenue YoY
PAT YoY
+303.0%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
1.2
P/S (TTM)
1.3
Sector P/E
36.3
Dividend yield
+0.6%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| ALBERTDAVD (this stock) | 17.7 | 1.2 | +6.2% | +5.8% | 0.08 | +0.6% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
stable
MF
0.01% (0.00pp)
stable
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedAlbert David Limited (ALBERTDAVD) reported no material defaults or regulatory penalties in FY2023-24, with a qualification-free audit report. The company faces pending tax disputes totaling ₹2,580.09 lakh, including ₹281.14 lakh disputed with others. Key risks include unresolved litigation and contingent liabilities, though no liquidity or solvency issues were noted. The company introduced new products and operates under the Kothari Group, maintaining compliance with governance standards.
- No defaults or regulatory penalties noted in FY2023-24.
- Pending tax disputes amounting to ₹2,580.09 lakh, including ₹281.14 lakh disputed with others.
- Audit report was qualification-free, indicating no material misstatements.
- Introduced new products like 'Evaston OD 10 mg' and 'Alamin SE' during the year.
- Corporate governance practices were in compliance with SEBI regulations.
Key takeaway: Albert David Limited maintains compliance and operational stability, but pending disputes and contingent liabilities require monitoring.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceOlder (3+ years ago)
The auditors expressed a material uncertainty regarding the company's ability to meet liabilities due within one year from the balance sheet date as of March 31, 2022.
Routine disclosures
Contingent Liability
5 occurrencesEarlier (1-3 years ago)
The company has contingent liabilities related to claims, disputes, and demands in excise, sales tax/VAT, custom duty, and other matters as of March 31, 2025 and 2024. These liabilities are not acknowledged as debts, and future cash flows are uncertain pending judicial outcomes, with no possibility of reimbursement.
The company is involved in pending litigations (direct, indirect tax and other) with different statutory authorities, which are disclosed as contingent liabilities in the financial statements. The amounts involved are potentially significant.
Older (3+ years ago)
The company is involved in pending litigations and claims related to direct, indirect tax and other matters with different statutory authorities, which are disclosed as contingent liabilities in the financial statements.
The company is involved in pending litigations related to direct, indirect tax and other matters with different statutory authorities, as disclosed in notes on contingent liability and provisions for contingencies.
The company is involved in pending litigations (direct, indirect tax and other) with different statutory authorities, which are disclosed as contingent liabilities and provisions for contingencies in the financial statements.
Related-Party Transaction
2 occurrencesEarlier (1-3 years ago)
The company has related party transactions, as detailed in Note No. 53 of its financial statements.
Older (3+ years ago)
The company has disclosed related-party transactions with entities where key managerial personnel and their relatives have significant influence, including Kothari Medical Centre, Satyam Financial Services Limited, and others.
Management & Board Governance
3 occurrencesEarlier (1-3 years ago)
Mr. Shirish Gundopant Belapure resigned as an Independent Director effective 10th March 2025 due to increasing professional commitments.
Older (3+ years ago)
Mr. T. S. Parmar, Managing Director & CEO, resigned from the Board effective December 8, 2022. Mr. A. V. Kothari was appointed as an Additional Director on May 11, 2022, and his appointment was regularized at the Annual General Meeting on August 9, 2022.
Dr. Indrajit Dhar, Associate Vice President (Accounts & Taxation)-cum-Company Secretary resigned from the post of Company Secretary & Compliance Officer of the Company with effect from 29th June, 2020.